VKTX

Company Overview — What Does Viking Therapeutics, Inc. Do?

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Viking Therapeutics, Inc. (VKTX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Brian Lian and employs approximately 20 people, headquartered in SAN DIEGO, California. With a market capitalization of $3.8B, VKTX is one of the notable companies in the Healthcare sector.

Viking Therapeutics, Inc. (VKTX) Stock Rating — Reduce (April 2026)

As of April 2026, Viking Therapeutics, Inc. receives a Reduce rating with a composite score of 29.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.VKTX ranks #2,114 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Viking Therapeutics, Inc. ranks #239 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VKTX Stock Price and 52-Week Range

Viking Therapeutics, Inc. (VKTX) currently trades at $34.24. The stock lost $0.71 (2.0%) in the most recent trading session. The 52-week high for VKTX is $43.15, which means the stock is currently trading -20.6% from its annual peak. The 52-week low is $18.92, putting the stock 81.0% above its annual trough. Recent trading volume was 1.7M shares, reflecting moderate market activity.

Is VKTX Overvalued or Undervalued? — Valuation Analysis

Viking Therapeutics, Inc. (VKTX) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.11x, versus the sector average of 2.75x.

At current multiples, Viking Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Viking Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Viking Therapeutics, Inc. (VKTX) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -35.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -31.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

VKTX Debt, Balance Sheet, and Financial Health

Viking Therapeutics, Inc. has a debt-to-equity ratio of 12.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.33x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $100M.

VKTX has a beta of 1.52, meaning it is more volatile than the broader market — a $10,000 investment in VKTX would be expected to move 51.7% more than the S&P 500 on any given day. The stability factor score for Viking Therapeutics, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Viking Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Viking Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.19. Net income for the quarter was $-227M. Operating income came in at $-265M.

In FY 2025, Viking Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.19. Net income for the quarter was $-360M. Operating income came in at $-393M.

In Q3 2025, Viking Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.81. Net income for the quarter was $-91M. Operating income came in at $-99M.

In Q2 2025, Viking Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.58. Net income for the quarter was $-66M. Operating income came in at $-75M.

Over the past 8 quarters, Viking Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing VKTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VKTX Dividend Yield and Income Analysis

Viking Therapeutics, Inc. (VKTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VKTX Momentum and Technical Analysis Profile

Viking Therapeutics, Inc. (VKTX) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

VKTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Viking Therapeutics, Inc. (VKTX) ranks #239 out of 838 stocks based on the Blank Capital composite score. This places VKTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VKTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VKTX vs S&P 500 (SPY) comparison to assess how Viking Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

VKTX Next Earnings Date

No upcoming earnings date has been announced for Viking Therapeutics, Inc. (VKTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VKTX? — Investment Thesis Summary

The quantitative profile for Viking Therapeutics, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. High volatility (stability score 31/100) increases portfolio risk.

In summary, Viking Therapeutics, Inc. (VKTX) earns a Reduce rating with a composite score of 29.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VKTX stock.

Related Resources for VKTX Investors

Explore more research and tools: VKTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VKTX head-to-head with peers: VKTX vs AZN, VKTX vs SLGL, VKTX vs VMD.